N-[3-[[6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]propyl]cyclobutanecarboxamide | 1365645-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[3-[[6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]propyl]cyclobutanecarboxamide
• CAS: 1365645-69-7
• 化学式: C₂₇H₃₅BrN₆O₂
• 分子量: 555.518
• InChiKey: HYCRTUWVJJGNKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  95.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-[2-(1-哌啶基)乙氧基]-苯甲酸 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 、 正丁醇 为溶剂， 反应 7.0h， 生成 N-[3-[[6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]propyl]cyclobutanecarboxamide
  参考文献：
  名称：

  Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases

  摘要：

  The design, synthesis and biological evaluation of a series of azabenzimidazole derivatives as TBK1/IKK epsilon kinase inhibitors are described. Starting from a lead compound 1a, iterative design and SAR exploitation of the scaffold led to analogues with nM enzyme potencies against TBK1/IKK epsilon. These compounds also exhibited excellent cellular activity against TBK1. Further structure-based design to improve selectivity over CDK2 and Aurora B resulted in compounds such as 5b-e. These probe compounds will facilitate study of the complex cancer biology of TBK1 and IKK epsilon. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.018

文献信息

• Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases
  作者：Tao Wang、Michael A. Block、Scott Cowen、Audrey M. Davies、Erik Devereaux、Lakshmaiah Gingipalli、Jeffrey Johannes、Nicholas A. Larsen、Qibin Su、Julie A. Tucker、David Whitston、Jiaquan Wu、Hai-Jun Zhang、Michael Zinda、Claudio Chuaqui

  DOI：10.1016/j.bmcl.2012.01.018

  日期：2012.3

  The design, synthesis and biological evaluation of a series of azabenzimidazole derivatives as TBK1/IKK epsilon kinase inhibitors are described. Starting from a lead compound 1a, iterative design and SAR exploitation of the scaffold led to analogues with nM enzyme potencies against TBK1/IKK epsilon. These compounds also exhibited excellent cellular activity against TBK1. Further structure-based design to improve selectivity over CDK2 and Aurora B resulted in compounds such as 5b-e. These probe compounds will facilitate study of the complex cancer biology of TBK1 and IKK epsilon. (C) 2012 Elsevier Ltd. All rights reserved.